[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338754-105":59,"doc-detail-338754-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-outcomes-of-everolimus-based-treatment-in-a-taiwanese-cohort-with-metastatic-hrher2-breast-cancer","Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2− breast cancer","","Background: Everolimus was the first orally targeted therapy for certain cancers and is widely used for advanced HR+/HER2− breast cancer. This real-world study evaluates its impact on overall survival (OS) and progression-free survival (PFS) across treatment lines, and examines its role in therapeutic strategies. Methods: 299 Taiwanese women with histologically confirmed HR+/HER2− metastatic breast cancer received everolimus-based treatment. Results: Median PFS was 5.6 months and median OS was 60.1 months, with distinct outcomes by line of therapy and metastasis sites. Conclusion: Findings support current guidelines and advocate everolimus inclusion in treatment plans, especially for late-line settings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-outcomes-of-everolimus-based-treatment-in-a-taiwanese-cohort-with-metastatic-hrher2-breast-cancer/338754/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-outcomes-of-everolimus-based-treatment-in-a-taiwanese-cohort-with-metastatic-hrher2-breast-cancer/338754.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of this study on everolimus in Taiwanese patients?","Question",{"text":112,"@type":113},"To assess how everolimus-based treatment affected overall survival (OS) and progression-free survival (PFS) by treatment line and to clarify its role in real-world therapeutic strategies for metastatic HR+/HER2− breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were PFS and OS outcomes estimated and compared?",{"text":117,"@type":113},"Survival curves were generated using the Kaplan-Meier method, comparisons used the log-rank test, and multivariate and univariate analyses used Cox proportional hazards regression.",{"name":119,"@type":110,"acceptedAnswer":120},"Which patient factors were associated with different PFS and OS results?",{"text":121,"@type":113},"Patients receiving everolimus in three or more lines and those who had chemotherapy before everolimus had shorter PFS but longer OS, while liver and central nervous system metastases were associated with shorter PFS and OS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338754,1790145729,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","J Chin MedAssoc  \nOriginal article  \nReal-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2− breast cancer  \nYun-Chieh Kaoa,b, Yi-Fang Tsaib,c,d, Shih-Che Shene, Ming-Shen Daif, Fang-Ming Cheng, Liang-Chih Liuh, Ta-Chung Chaoa,b,c, Chi-Cheng Huangb,c,d, Ming-Feng Houg, Shin-Cheh Chene, Chun-Yu Liua,b,c,*,  \nLing-Ming Tsengb,c,d,*  \naDivision of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cComprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; dDivision of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; eDivision of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC; fDivision of Hematology and Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC; gDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC; hDepartment of Surgery, China Medical University Hospital, Taichung, Taiwan, ROC  \nAbstract  \nBackground: Everolimus was the first orally targeted therapy for certain cancers. It was introduced before CDK4/6 inhibitors and is widely used to treat advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer. This study presents comprehensive findings including updated data and long-term survival analyses focusing on patients with HR+/HER2− metastatic breast cancer who received everolimus-based treatment. The objectives were to assess the impact of everolimus on overall survival (OS) and progression-free survival (PFS) by treatment line, and to evaluate its role in therapeutic strategies in a real-world setting.  \nMethods: We included 299 women aged over 20 years with histologically confirmed HR+/HER2− breast cancer who received everolimus-based treatment from multiple medical centers in Taiwan. Survival curves were generated using the Kaplan-Meier method, with the log-rank test for comparisons. Univariate and multivariate analyses were performed using a Cox proportional hazards regression model. Adverse effects were graded according to the Common Terminology Criteria for Adverse Events version 5.0.  \nResults: The median PFS was 5.6 months, and the median OS was 60.1 months. Patients receiving everolimus treatment in three or more lines and those who underwent chemotherapy before everolimus-based treatment had a significantly shorter PFS but longer OS. Patients with liver and central nervous system metastases had significantly shorter PFS and OS. The disease control rate was 51.5%, and the overall response rate was 8.0% .  \nConclusion: These findings support current guidelines and advocate for the inclusion of everolimus in treatment plans for patients with metastatic HR+/HER2− breast cancer, particularly in late-line treatment, with careful consideration of the benefit-risk profile for each patient.  \nKeywords: Breast cancer; Everolimus; Liver; Progression-free survival; Taiwan  \n*Address correspondence. Dr. Chun-Yu Liu, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, 155, Section 2, Linong Street, Taipei 112, Taiwan, ROC, [E-mail address: cyliu3@vghtpe.gov.tw](E-mail address: cyliu3@vghtpe.gov.tw) (C.-Y. Liu); Dr. Ling-Ming Tseng, Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, ROC. E-mail address: [lmtseng@vghtpe.gov.tw](lmtseng@vghtpe.gov.tw) (L.-M. Tseng). Conflicts of interest: Dr. Chun-Yu Liu and Dr. Ling-Ming Tseng, editorial board member at the Journal of the Chinese Medical Association, had no role in the peer review process or decision to publish this article. The other authors declare that they have no conflicts of inte","cbCaims3SWs0BmZe","https://ap.wps.com/l/cbCaims3SWs0BmZe","pdf",1163186,"English","# Introduction\n## Patient population and rationale for real-world assessment\n# Methods\n## Study design, cohort, and statistical analyses\n# Results\n## Survival outcomes and response measures\n# Conclusion","[{\"question\":\"What was the main purpose of this study on everolimus in Taiwanese patients?\",\"answer\":\"To assess how everolimus-based treatment affected overall survival (OS) and progression-free survival (PFS) by treatment line and to clarify its role in real-world therapeutic strategies for metastatic HR+/HER2− breast cancer.\"},{\"question\":\"How were PFS and OS outcomes estimated and compared?\",\"answer\":\"Survival curves were generated using the Kaplan-Meier method, comparisons used the log-rank test, and multivariate and univariate analyses used Cox proportional hazards regression.\"},{\"question\":\"Which patient factors were associated with different PFS and OS results?\",\"answer\":\"Patients receiving everolimus in three or more lines and those who had chemotherapy before everolimus had shorter PFS but longer OS, while liver and central nervous system metastases were associated with shorter PFS and OS.\"}]","Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2− breast cancer | PDF",1790025457,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8713dba0e53b9d5407bfdc11201e8a7.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6acb7f2f24e15f64fba51c02d1acd262.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e551f5a4e10bfd6ecaac34f5d040b552.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc0ee2da907fbe1d60164b209775f65b.webp",980,1306]